Cargando…

Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center

Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period...

Descripción completa

Detalles Bibliográficos
Autores principales: Turcu-Stiolica, Adina, Subtirelu, Mihaela-Simona, Bumbea, Ana-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303388/
https://www.ncbi.nlm.nih.gov/pubmed/34356168
http://dx.doi.org/10.3390/brainsci11070934
_version_ 1783727074932948992
author Turcu-Stiolica, Adina
Subtirelu, Mihaela-Simona
Bumbea, Ana-Maria
author_facet Turcu-Stiolica, Adina
Subtirelu, Mihaela-Simona
Bumbea, Ana-Maria
author_sort Turcu-Stiolica, Adina
collection PubMed
description Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period: botulinum toxin type A (BOT) with conventional therapy (CON). We also assessed the reduction of spasticity and functionality secondary to the increase in the mobility in upper limbs. This study was based on a prospective, randomized design, including subjects with post-stroke spasticity (N = 34; 34–80 years of age): in the CON arm, patients received therapy against muscle spasticity and physiotherapy, and, in the BOT arm, patients received incobotulinumtoxin-A and additionally conventional treatment, if required. Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy (p < 0.001), represented by improvement in movement (p < 0.001), usual activities (p = 0.018), and distress (p < 0.001). Improvements in muscle tone (Ashworth Scale) over 6 months of treatment period were greater in the BOT arm (100%) than in the CON arm (11.8%). These preliminary results suggested that incobotulinumtoxin-A increased quality of life by improving movement, daily activities, mental health, and muscle tone more effectively than conventional therapy and could form a basis for future comparator studies.
format Online
Article
Text
id pubmed-8303388
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83033882021-07-25 Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center Turcu-Stiolica, Adina Subtirelu, Mihaela-Simona Bumbea, Ana-Maria Brain Sci Article Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period: botulinum toxin type A (BOT) with conventional therapy (CON). We also assessed the reduction of spasticity and functionality secondary to the increase in the mobility in upper limbs. This study was based on a prospective, randomized design, including subjects with post-stroke spasticity (N = 34; 34–80 years of age): in the CON arm, patients received therapy against muscle spasticity and physiotherapy, and, in the BOT arm, patients received incobotulinumtoxin-A and additionally conventional treatment, if required. Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy (p < 0.001), represented by improvement in movement (p < 0.001), usual activities (p = 0.018), and distress (p < 0.001). Improvements in muscle tone (Ashworth Scale) over 6 months of treatment period were greater in the BOT arm (100%) than in the CON arm (11.8%). These preliminary results suggested that incobotulinumtoxin-A increased quality of life by improving movement, daily activities, mental health, and muscle tone more effectively than conventional therapy and could form a basis for future comparator studies. MDPI 2021-07-15 /pmc/articles/PMC8303388/ /pubmed/34356168 http://dx.doi.org/10.3390/brainsci11070934 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Turcu-Stiolica, Adina
Subtirelu, Mihaela-Simona
Bumbea, Ana-Maria
Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
title Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
title_full Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
title_fullStr Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
title_full_unstemmed Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
title_short Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
title_sort can incobotulinumtoxin-a treatment improve quality of life better than conventional therapy in spastic muscle post-stroke patients? results from a pilot study from a single center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303388/
https://www.ncbi.nlm.nih.gov/pubmed/34356168
http://dx.doi.org/10.3390/brainsci11070934
work_keys_str_mv AT turcustiolicaadina canincobotulinumtoxinatreatmentimprovequalityoflifebetterthanconventionaltherapyinspasticmusclepoststrokepatientsresultsfromapilotstudyfromasinglecenter
AT subtirelumihaelasimona canincobotulinumtoxinatreatmentimprovequalityoflifebetterthanconventionaltherapyinspasticmusclepoststrokepatientsresultsfromapilotstudyfromasinglecenter
AT bumbeaanamaria canincobotulinumtoxinatreatmentimprovequalityoflifebetterthanconventionaltherapyinspasticmusclepoststrokepatientsresultsfromapilotstudyfromasinglecenter